A Double-Blind, Active-Controlled, Multiple-Ascending Dose Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeru

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Cori Daines
Sponsor
Respirion Pharmaceuticals Pty Ltd (Australia)
Unit
Asthma/Airway Disease Rsch Ctr